On June 20th, Gelunhui learned that Luye Pharma Group announced that its independently developed innovative microsphere preparation - Jinyouping (injection of rosuvastatin microspheres), as a variety included in the priority review and approval procedure, has obtained the market approval of the Chinese National Medical Products Administration for the treatment of Parkinson's disease. The pharmaceutical is developed based on Luye Pharma's microsphere technology platform, administered once a week, and is the world's first long-acting sustained-release microsphere formulation for the treatment of Parkinson's disease.
全球首个治疗帕金森病长效微球制剂金悠平在华获批上市
The world's first long-acting microsphere preparation for treating Parkinson's disease, Jin Youping, has been approved for listing in China.
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.